WDAY — Transition Period Ends for Sayan Chakraborty
Jun 2, 2025, 8:00:00 AM UTC
Summary
Sayan Chakraborty will conclude his advisory role with Workday, Inc. on June 2, 2025, assisting in the transition of duties after serving as President, Product and Technology. His retirement from this executive position was reported along with the appointment of Gerrit Kazmaier to succeed him, effective March 10, 2025. During the transition period, Chakraborty will maintain his current compensation and continue to facilitate the handover. Following the transition, he is expected to enter into a consulting agreement with Workday to provide advisory services until December 2, 2025, where he will continue to vest his prior equity awards.
Company
WORKDAY INC (WDAY)NASDAQ — Technology: Services, Software - Application: Services-Computer Processing & Data Preparation
www.workday.comSimilar Events
Consulting Agreement Ends for Sayan Chakraborty
Sayan Chakraborty's consulting agreement with Workday, Inc. concludes on December 2, 2025, marking the end of his advisory services following his transition from the role of President, Product and Technology. His departure coincides with Gerrit Kazmaier’s appointment to the role, effective March 10, 2025. Chakraborty is expected to continue receiving his cash compensation and vesting equity awards through the end of his agreement, which reflects his significant contributions to the company during his tenure. The end of this transition period and consulting role signals a strategic leadership shift for Workday as it enhances its product and innovation strategy under Kazmaier's leadership.
Consulting Agreement EndSubscription Period Ends
Realfiction Holding AB will conclude its subscription period for a rights issue on August 15, 2025. The rights issue aims to raise approximately SEK 50 million to support the company’s commercial activities related to its Directional Pixel Technology (DPT). Shareholders are entitled to subscribe at a price of SEK 15.00 per unit, each comprising two new shares and one warrant. If fully subscribed, the issue will also lead to a significant dilution of about 25% for existing shareholders. The company's board of directors postponed the annual general meeting to June 30, 2025, which is essential for the approval of this rights issue, amid ongoing negotiations concerning outstanding loans as part of the company’s strategic financial restructuring and growth plans.
Subscription Period EndsSubscription Period Ends
Bioretec Ltd announced the end of the subscription period for its rights issue, which allows existing shareholders to purchase up to 6,156,618 new shares at a price of EUR 1.50 each. The subscription period runs from June 5 to June 19, 2025. The offering is supported by an exemption document in compliance with EU regulations. Bioretec, a Finnish medical device company, focuses on biodegradable orthopedic implants to enhance bone growth and facilitate recovery. The company recently received CE mark approval in January 2025 for its RemeOs™ product line, which aims to transform surgical bone fracture treatment and target the significant global orthopedic trauma market exceeding USD 10 billion.
Subscription Period EndsEnd of Consulting Period for Amar Murugan
The consulting agreement between Amar Murugan and Atara Biotherapeutics, Inc. is set to end on July 11, 2025. Murugan, previously the Chief Legal Officer at Atara, transitioned to a consultancy role after his employment ended on November 8, 2024. Under the consulting agreement, Murugan is required to work up to 10 hours per month at an hourly rate of $250, relinquish all stock options, and maintain vesting of his restricted stock units during the term. He is entitled to bonuses contingent upon FDA approval and the transfer of tabelecleucel manufacturing to Pierre Fabre Medicament. This transition is significant for Atara, as tabelecleucel is a key asset and its successful commercialization will have financial implications for the company.
Consulting Period End